Notably, PXN expression is significantly upregulated in various malignant cancers, including prostate cancer, bladder cancer, cervical cancer, esophageal cancer, and melanoma, compared with that in adjacent nontumor tissues [17, 18]. Here, PXN is linked to urinary bladder carcinoma.